Mukherjee Herschel, Chan Kok-Ping, Andresen Vibeke, Hanley Mariah L, Gjertsen Bjørn Tore, Myers Andrew G
†Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford Street, Cambridge, Massachusetts 02138, United States.
‡Centre for Cancer Biomarkers, CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.
ACS Chem Biol. 2015 Mar 20;10(3):855-63. doi: 10.1021/cb500872g. Epub 2015 Jan 5.
Nucleophosmin (NPM1) is a multifunctional phosphoprotein localized predominantly within the nucleoli of eukaryotic cells. Mutations within its C-terminal domain are frequently observed in patients with acute myeloid leukemia (AML), are thought to play a key role in the initiation of the disease, and result in aberrant, cytoplasmic localization of the mutant protein. We have previously shown that the electrophilic antiproliferative natural product (+)-avrainvillamide (1) binds to proteins, including nucleophosmin, by S-alkylation of cysteine residues. Here, we report that avrainvillamide restores nucleolar localization of certain AML-associated mutant forms of NPM1 and provide evidence that this relocalization is mediated by interactions of avrainvillamide with mutant NPM1 and exportin-1 (Crm1). Immunofluorescence and mass spectrometric experiments employing a series of different NPM1 constructs suggest that a specific interaction between avrainvillamide and Cys275 of certain NPM1 mutants mediates the relocalization of these proteins to the nucleolus. Avrainvillamide treatment is also shown to inhibit nuclear export of Crm1 cargo proteins, including AML-associated NPM1 mutants. We also observe that avrainvillamide treatment displaces Thr199-phosphorylated NPM1 from duplicated centrosomes, leads to an accumulation of supernumerary centrosomes, and inhibits dephosphorylation of Thr199-phosphorylated NPM1 by protein phosphatase 1. Avrainvillamide is the first small molecule reported to relocalize specific cytoplasmic AML-associated NPM1 mutants to the nucleolus, providing an important demonstration of principle that small molecule induction of a wild-type NPM1 localization phenotype is feasible in certain human cancer cells.
核磷蛋白(NPM1)是一种多功能磷蛋白,主要定位于真核细胞的核仁内。急性髓系白血病(AML)患者中经常观察到其C端结构域内的突变,这些突变被认为在该疾病的起始中起关键作用,并导致突变蛋白异常定位于细胞质中。我们之前已经表明,亲电抗增殖天然产物(+)-阿维拉米德(1)通过半胱氨酸残基的S-烷基化与包括核磷蛋白在内的蛋白质结合。在此,我们报告阿维拉米德可恢复某些与AML相关的NPM1突变形式的核仁定位,并提供证据表明这种重新定位是由阿维拉米德与突变型NPM1和输出蛋白-1(Crm1)的相互作用介导的。使用一系列不同NPM1构建体的免疫荧光和质谱实验表明,阿维拉米德与某些NPM1突变体的Cys275之间的特异性相互作用介导了这些蛋白质向核仁的重新定位。阿维拉米德处理还显示可抑制Crm1货物蛋白的核输出,包括与AML相关的NPM1突变体。我们还观察到,阿维拉米德处理可使 Thr199磷酸化的NPM1从复制的中心体上移位,导致多余中心体的积累,并抑制蛋白磷酸酶1对Thr199磷酸化的NPM1的去磷酸化。阿维拉米德是首个被报道可将特定的细胞质AML相关NPM1突变体重定位至核仁的小分子,这为在某些人类癌细胞中通过小分子诱导野生型NPM1定位表型的可行性提供了重要的原理证明。